CDKN2A and cervical cancer: In HeLa cells, PRMT6 can also interact with p16 to methylate it and reduce the association of p16 and CDK4, suggesting that PRMT6 inhibits cell apoptosis through p16 arginine methylation, which also makes p16-associated gene therapy for cervical cancer a possible new strategy (78).